Enliven Therapeutics
ELVN
170 hedge funds and large institutions have $2.43B invested in Enliven Therapeutics in 2026 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 62 increasing their positions, 32 reducing their positions, and 19 closing their positions.
400% more funds holding in top 10
Funds holding in top 10: 2 → 10 (+8)
242% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 19
200% more call options, than puts
Call options by funds: $48.3M | Put options by funds: $16.1M
153% more capital invested
Capital invested by funds: $961M → $2.43B (+$1.47B)
94% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 32
36% more funds holding
Funds holding: 125 → 170 (+45)
0.8% less ownership
Funds ownership: 105.13% → 104.33% (-0.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$64.3M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$43M |
| 3 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$20.7M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$20.4M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$17.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$51.4M |
| 2 |
Janus Henderson Group
London,
|
-$46M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$41.7M |
| 4 |
VA
VR Adviser
New York
|
-$41.6M |
| 5 |
CC
Commodore Capital
New York
|
-$39.3M |
ELVN Hedge Fund Activity: Q1 2026 in Review
170 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q1 2026, worth a combined $2.43B — up 153% from $961M a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new ELVN positions and 19 closed out — a net gain of 46 holders — while 62 added to existing stakes and 32 trimmed.
The largest buyer was Bellevue Group, opening a new position worth an estimated $64.3M. The largest seller was Fairmount Funds Management, cutting an estimated $51.4M.
- 170 institutional investors held Enliven Therapeutics (ELVN) as of Q1 2026, up from 125 in Q4 2025.
- Funds reported $2.43B of Enliven Therapeutics stock for Q1 2026, up 153% quarter-over-quarter.
- 65 funds opened new Enliven Therapeutics positions in Q1 2026 and 19 closed out, a net change of +46 holders.
- The largest Enliven Therapeutics buyer in Q1 2026 was Bellevue Group, an estimated $64.3M added.
- The largest Enliven Therapeutics seller in Q1 2026 was Fairmount Funds Management, an estimated $51.4M sold.
Based on aggregated 13F filings for Q1 2026.